Loading
A phase 3 trial of Xaluritamig, Abiraterone acetate, Docetaxel in prostate cancer, run by Amgen, now recruiting.
A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer is a phase 3 interventional study registered as NCT07213674 by Amgen, with 750 participants planned, started 2025-11-28 and due to reach its primary completion in 2030-01-07. Interventions recorded: Xaluritamig, Abiraterone acetate, Docetaxel, Cabazitaxel. Conditions listed: Metastatic Castration-resistant Prostate Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Xaluritamig, Cabazitaxel, Amgen, T-cell engagers (bispecific).
Shares Cabazitaxel, Docetaxel, Metastatic castration-resistant prostate cancer, Prostate cancer.
Shares Abiraterone acetate, Docetaxel, Metastatic castration-resistant prostate cancer, Prostate cancer.
Shares Cabazitaxel, Abiraterone acetate, Metastatic castration-resistant prostate cancer, Prostate cancer.
Shares T-cell engagers (bispecific), Docetaxel, Metastatic castration-resistant prostate cancer, Prostate cancer.
Shares Cabazitaxel, Docetaxel, Metastatic castration-resistant prostate cancer, Prostate cancer.
Shares Abiraterone acetate, Metastatic castration-resistant prostate cancer, Prostate cancer.
Shares Abiraterone acetate, Docetaxel, Metastatic castration-resistant prostate cancer, Prostate cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/